Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.
暂无分享,去创建一个
X. Puente | J. Baselga | E. Felip | P. Nuciforo | J. Seoane | J. Arribas | M. Scaltriti | A. Vivancos | V. Serra | J. Hernández-Losa | L. De Mattos-Arruda | D. Silberschmidt | J. Grueso | L. Prudkin | G. Caratù | J. Parra | X. S. Puente | G. Caratù
[1] S. Peters,et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[3] James S. Duncan,et al. Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models , 2012, Clinical Cancer Research.
[4] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[5] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[6] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[7] S. Kobayashi,et al. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.
[8] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[9] M. Mathieu,et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome , 2010, Radiation oncology.
[10] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[11] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[12] M. Meyerson,et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.
[13] Violeta Serra,et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. , 2008, Cancer research.
[14] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[15] E. Rowinsky,et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[17] F. Cappuzzo,et al. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.
[18] W. Park,et al. Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.
[19] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[20] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[21] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[22] D. Stern,et al. Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface , 1998, Molecular and Cellular Biology.
[23] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[24] Cori Bargmann,et al. The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.
[25] Cori Bargmann,et al. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.
[26] Robert A. Weinberg,et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.
[27] J. Trimmer,et al. Monoclonal antibody to a membrane glycoprotein inhibits the acrosome reaction and associated Ca2+ and H+ fluxes of sea urchin sperm , 1985, Cell.
[28] R. Weinberg,et al. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene , 1984, Nature.